 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
The company plans to develop a range of complementary anti-hCG therapeutic products for cancer.
| • | CG201, the anti-hCG vaccine. CG201 is the company’s lead product in late stage development for treating solid tumor cancers. CG201 inoculations target hCG-producing tumors by stimulating patients’ immune systems to produce antibodies that eliminate hCG. This product is the result of a 20 year, multi-organizational effort with a $30 million investment. Two new, randomized Phase 2 trials are scheduled for 2008 in patients with advanced non small cell lung cancer and colorectal cancer to confirm positive results from earlier colorectal and pancreatic cancer Phase 2 trials. In the future, the company plans to study CG201’s effectiveness in additional Phase 2 trials with solid tumor cancers such as ovarian, prostate, pancreatic and breast. Other plans include studying co-therapy applications of CG201 with chemotherapeutic agents, monoclonal antibodies against hCG and developing further improvements to the vaccine itself. |
| • | Anti-hCG monoclonal antibodies. CGT plans to develop or in-license anti-hCG human monoclonal antibodies with unique properties for use in treating cancer, particularly in combination with CG201. |
| • | Other therapies. CGT has an interest in exploring the clinical applications of other anti-hCG approaches including combination therapies using its anti-hCG products in combination with other experimental or established cancer therapeutic agents. |
